Steensrud Tor, Nordhaug Dag, Husnes Kjell V, Aghajani Ebrahim, Sørlie Dag G
Department of Cardiothoracic and Vascular Surgery, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway.
Ann Thorac Surg. 2004 Apr;77(4):1391-7. doi: 10.1016/j.athoracsur.2003.09.076.
To determine whether the adenosine triphosphate-sensitive potassium channel opener nicorandil, instead of potassium in cold crystalloid cardioplegia, may enhance cardioprotection, crystalloid cardioplegia with nicorandil, magnesium, and procaine was compared with standard crystalloid cardioplegia in terms of left ventricular performance and efficiency.
Sixteen pigs were randomly assigned to receive cold hyperkalemic crystalloid cardioplegia (n = 8) or nicorandil in cold saline (n = 8). Cold (4 degrees C) cardioplegic solutions were given antegradely and intermittently, with a cross-clamp time of 60 minutes. The preload recruitable stroke work relationship (PRSW), pressure-volume area (PVA), and myocardial oxygen consumption (MVO(2)) were calculated at baseline and at one and two hours following cross-clamp release, using combined pressure-volume conductance catheters, coronary flow probes, and O(2)-content differences.
The left ventricular contractility expressed in PRSW was reduced to 58% (standard deviation [SD]: 20) of baseline in the crystalloid group and to 89% (SD: 20) in the nicorandil group two hours after cross-clamp release (p = 0.044). The slope of the MVO(2)-PVA relationship increased in the crystalloid group from 1.59 (SD: 0.22) before cardioplegia to 2.55 (SD: 0.73) afterwards, significantly more than in the nicorandil group, where the slope changed from 1.69 (SD: 0.30) to 1.95 (SD: 0.47) (p = 0.027).
Nicorandil in a crystalloid cardioplegic solution was easily employed and contractility was significantly better than after standard hyperkalemic cardioplegia. The smaller shift of the slope in the MVO(2)-PVA relationship in the nicorandil group shows improved efficiency in oxygen to mechanical transfer compared with the crystalloid group.
为了确定三磷酸腺苷敏感性钾通道开放剂尼可地尔而非冷晶体心脏停搏液中的钾是否可增强心脏保护作用,将含有尼可地尔、镁和普鲁卡因的晶体心脏停搏液与标准晶体心脏停搏液在左心室功能和效率方面进行了比较。
16只猪被随机分为两组,分别接受冷高钾晶体心脏停搏液(n = 8)或冷盐水中的尼可地尔(n = 8)。冷(4℃)心脏停搏液顺行间断给予,主动脉阻断时间为60分钟。使用联合压力-容积导管、冠状动脉流量探头和氧含量差,在基线以及主动脉阻断解除后1小时和2小时计算预负荷可募集搏功关系(PRSW)、压力-容积面积(PVA)和心肌耗氧量(MVO₂)。
主动脉阻断解除后2小时,晶体组以PRSW表示的左心室收缩力降至基线的58%(标准差[SD]:20),而尼可地尔组降至89%(SD:20)(p = 0.044)。晶体组MVO₂-PVA关系的斜率从心脏停搏前的1.59(SD:0.22)增加至停搏后的2.55(SD:0.73),显著高于尼可地尔组,后者斜率从1.69(SD:0.30)变为1.95(SD:0.47)(p = 0.027)。
晶体心脏停搏液中的尼可地尔易于应用,其收缩力显著优于标准高钾心脏停搏液后的收缩力。与晶体组相比,尼可地尔组MVO₂-PVA关系斜率变化较小,表明氧向机械转换的效率提高。